Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
19 Settembre 2023 - 10:00PM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage
biopharmaceutical company developing a novel therapeutic that
targets toxic soluble amyloid beta oligomers for the treatment of
Alzheimer’s disease, announced today that management will
participate in a panel discussion at the Cantor Global Healthcare
Conference on Tuesday, Sept. 26, 2023 at 9:20 a.m.
ET. The live webcast may be accessed under the Investors tab
on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals,
Inc.
Acumen, headquartered in Charlottesville, VA, with
clinical operations based in Carmel, IN, is a clinical-stage
biopharmaceutical company developing a novel therapeutic that
targets toxic soluble amyloid beta oligomers (AβOs) for the
treatment of Alzheimer’s disease (AD). Acumen’s scientific founders
pioneered research on AβOs, which a growing body of evidence
indicates are early and persistent triggers of Alzheimer’s disease
pathology. Acumen is currently focused on advancing its
investigational product candidate, ACU193, a humanized monoclonal
antibody that selectively targets toxic soluble AβOs, following
positive topline results in INTERCEPT-AD, a Phase 1 clinical trial
involving early Alzheimer’s disease patients. For more information,
visit www.acumenpharm.com.
Investors: Alex
Braunabraun@acumenpharm.com
Media: AcumenPR@westwicke.com
Grafico Azioni Acumen Pharmaceuticals (NASDAQ:ABOS)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Acumen Pharmaceuticals (NASDAQ:ABOS)
Storico
Da Mag 2023 a Mag 2024